A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan

被引：9

作者：

Li, Yi-Heng ^{[1
]}

Chen, Jaw-Wen ^{[2
]}

Lin, Tsung-Hsien ^{[3
]}

Wang, Yu-Chen ^{[4
]}

Wu, Chau-Chung ^{[5
,6
]}

Yeh, Hung-, I ^{[7
,8
]}

Huang, Chin-Chou ^{[9
,10
]}

Chang, Kuan-Cheng ^{[11
,12
]}

Wu, Cho-Kai ^{[13
,14
]}

Chen, Po-Wei ^{[1
]}

Huang, Chen-Wei ^{[1
]}

Chen, Zhih-Cherng ^{[15
,16
]}

Chang, Wei-Ting ^{[15
]}

Huang, Wei-Chun ^{[17
]}

Wang, Chih-Yuan ^{[18
]}

Lee, Mei-Yueh ^{[19
,20
]}

Chao, A-Ching ^{[21
,22
,23
]}

Fu, Wei-Ren ^{[24
]}

Tsai, Li-Kai ^{[25
]}

Tang, Sung-Chun ^{[25
]}

Chan, Hsin-Lung ^{[26
]}

Yang, Yi-Ching ^{[27
]}

Wu, Yen-Wen ^{[28
,29
]}

Hwang, Juey-Jen ^{[14
,30
,31
]}

Lin, Jiunn-Lee ^{[14
,30
,32
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Cardiol, Tainan, Taiwan

[2] Natl Yang Ming Univ, Taipei Vet Gen Hosp & Inst Pharmacol, Dept Med Res & Educ, Taipei, Taiwan

[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp & Fac Med, Coll Med, Dept Internal Med,Div Cardiol, Kaohsiung, Taiwan

[4] China Med Univ, Asia Univ Hosp, Dept Internal Med, Div Cardiol,Coll Med & Hosp, Taichung, Taiwan

[5] Natl Taiwan Univ, Div Cardiol, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan

[6] Natl Taiwan Univ, Grad Inst Med Educ & Bioeth, Coll Med, Taipei, Taiwan

[7] Mackay Mem Hosp, Dept Internal Med & Med Res, Taipei, Taiwan

[8] Mackay Med Coll, Dept Med, New Taipei, Taiwan

[9] Taipei Vet Gen Hosp, Dept Med Educ, Dept Med, Div Cardiol, Taipei, Taiwan

[10] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan

[11] China Med Univ, China Med Univ Hosp, Dept Internal Med, Div Cardiovasc Med, Taichung, Taiwan

[12] China Med Univ, Coll Med, Taichung, Taiwan

[13] Natl Taiwan Univ Hosp, Div Cardiol, Dept Internal Med, 7 Chung Shan South Rd, Taipei, Taiwan

[14] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[15] Chi Mei Med Ctr, Dept Internal Med, Div Cardiol, Tainan, Taiwan

[16] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan

[17] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Cardiol, Kaohsiung, Taiwan

[18] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei, Taiwan

[19] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Kaohsiung, Taiwan

[20] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Fac Med, Kaohsiung, Taiwan

[21] Kaohsiung Med Univ Hosp, Dept Neurol, Kaohsiung, Taiwan

[22] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung, Taiwan

[23] Kaohsiung Med Univ, Dept Neurol, Coll Med, Kaohsiung, Taiwan

[24] Mackay Mem Hosp, Dept Neurol, Taipei, Taiwan

[25] Natl Taiwan Univ Hosp, Stroke Ctr & Dept Neurol, Taipei, Taiwan

[26] Mackay Mem Hosp, Mackay Med Coll, Dept Family Med, Dept Med, Taipei, Taiwan

[27] Natl Cheng Kung Univ, Dept Family Med, Natl Cheng Kung Univ Hosp, Coll Med, Tainan, Taiwan

[28] Far Eastern Mem Hosp, Cardiovasc Med Ctr, Cardiol Div, New Taipei, Taiwan

[29] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan

[30] Natl Taiwan Univ Hosp, Cardiol Div, Dept Internal Med, Taipei, Taiwan

[31] Natl Taiwan Univ Hosp Yun Lin, Dept Internal Med, Div Cardiol, Yunlin, Taiwan

[32] Taipei Med Univ, Dept Internal Med, Div Cardiovasc Med, Shuang Ho Hosp, New Taipei, Taiwan

来源：

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | 2020年 / 119卷 / 03期

关键词：

Atherosclerosis; Risk factors; Performance guide; PERIPHERAL ARTERY-DISEASE; BLOOD-PRESSURE TARGETS; BETA-BLOCKERS; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; COLLABORATIVE METAANALYSIS; ANTIHYPERTENSIVE TREATMENT; HYPERTENSIVE PATIENTS; ATRIAL-FIBRILLATION; ISCHEMIC-STROKE;

D O I：

10.1016/j.jfma.2019.04.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease, cerebrovascular disease, and peripheral artery disease, carries a high morbidity and mortality. Risk factor control is especially important for patients with ASCVD to reduce recurrent cardiovascular events. Clinical guidelines have been developed by the Taiwan Society of Cardiology, Taiwan Society of Lipids and Atherosclerosis, and Diabetes Association of Republic of China (Taiwan) to assist health care professionals in Taiwan about the control of hypertension, hypercholesterolemia and diabetes mellitus. This article is to highlight the recommendations about blood pressure, cholesterol, and sugar control for ASCVD. Some medications that are beneficial for ASCVD were also reviewed. We hope the clinical outcomes of ASCVD can be improved in Taiwan through the implementation of these recommendations. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC.

引用

页码：674 / 684

页数：11

共 77 条

[1] Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention [J].